Mumbai, Sept 26(UNI)Vivimed Labs has signed definitive agreements to facilitate an investment of USD 42.5 million by OrbiMed Asia into the company's subsidiary, Vivimed Labs Mascarene, the holding entity of the company's API business, UQUIFA. The proceeds of this fund raise will be utilized by the company primarily for Debt reduction and optimization of capital structure at the parent entity level and investment in the API business for capacity augmentation and organic growth. Commenting on the development, Mr, Santosh Varalwar, Managing Director said "Vivimed welcomes the investment by orbiMed in our business as we prepare ourselves to embark on the next lap of growth for our API franchise. UQUIFA, today, is a significant part of vivimed,s presence in the pharmaceuticals business and is poised to grow well ahead of the industry on the back of our strategic initiatives and investments committed. Even as we have seen a scale up in the sales and profitability metrics from this part of the business in the recent past,we are confident that high value opportunities in our targeted segments of the market will drive the future. UNI JS SM1222